Tumors can evade immune detection by exploiting inhibitory immune checkpoints such as
the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway …

Abstract Jiangsu Chia-Tai Tianqing Pharmaceutical and Advenchen Laboratories are co-
developing anlotinib (Focus V®) for the treatment of advanced cancer. Anlotinib is an oral …

Lung cancer is the foremost cause of cancer-related deaths world-wide. Both, the major
forms of lung cancer, Non-small cell lung cancer (NSCLC) and Small cell lung cancers …

Anti-programmed cell death-1 and anti-programmed cell death ligand-1 (PD-L1)
monotherapies have shown promising clinical activity in advanced, refractory non–small-cell …

LINC‐PINT is a p53‐induced long intergenic noncoding transcript that plays a crucial role in
many diseases, especially cancer. This long noncoding RNA (lncRNA) gene produces in …

Lung cancer continues to pose a significant challenge as a prominent contributor to global
cancer-related mortality. Despite the considerable strides made in therapeutic interventions …

New drugs introduced to the market every year represent privileged structures for particular
biological targets. These new chemical entities (NCEs) provide insight into molecular …

The prognosis for patients with relapsed/progressive non-small cell lung cancer (NSCLC)
remains poor. For first-line therapy, a number of platinum-based regimens are standard; …

Background Systemic anti-cancer therapy (SACT) is the recommended treatment modality in
patients with advanced non-small cell lung cancer (aNSCLC) in clinical guidelines. SACT …

Most of patients with newly diagnosed non-small cell lung cancer (NSCLC) present with
locally advanced or metastatic disease. In this setting the goal of treatment is to prolong …